| 0.4401 -0.06 (-11.98%) | 03-18 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.88 | 1-year : | 1.02 |
| Resists | First : | 0.75 | Second : | 0.87 |
| Pivot price | 0.69  |
|||
| Supports | First : | 0.55 | Second : | 0.45 |
| MAs | MA(5) : | 0.65 |
MA(20) : | 0.69 |
| MA(100) : | 0.98 |
MA(250) : | 4.11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.1 |
D(3) : | 25.3 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 14.88 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LYRA ] has closed below the lower bollinger band by 4.4%. Bollinger Bands are 63.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.76 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.6 - 0.6 | 0.6 - 0.6 |
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
Wed, 17 Jun 2026
Lyra Therapeutics Inc (LYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Wed, 17 Jun 2026
Lyra Therapeutics Inc (LYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fri, 17 Apr 2026
Lyra Therapeutics (LYRA) Plans Voluntary Delisting from Nasdaq - GuruFocus
Fri, 17 Apr 2026
Lyra stock trades on Pink market as company moves to end SEC registration - Stock Titan
Mon, 13 Apr 2026
After layoffs, Lyra Therapeutics exits Watertown and Waltham leases - The Business Journals
Fri, 10 Apr 2026
Lyra Therapeutics to end leases early for Watertown and Waltham facilities - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -18 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.77e+006 (%) |
| Held by Institutions | 336130 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -608000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -18.63 |
| Profit Margin | 0 % |
| Operating Margin | -98 % |
| Return on Assets (ttm) | 728.5 % |
| Return on Equity (ttm) | -36.1 % |
| Qtrly Rev. Growth | 594.9 % |
| Gross Profit (p.s.) | -1744 |
| Sales Per Share | -8089.61 |
| EBITDA (p.s.) | -3.96e+008 |
| Qtrly Earnings Growth | -2.909e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.03 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 16530 |
| Forward Dividend | 59090 |
| Dividend Yield | 3005450% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|